Skip to main content

Table 2 Bioequivalence evaluation (expressed as 90%CI of the Ln-transformed ratio, except for tmax, which is expressed as 90%CI of the untransformed differences)

From: Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations

 

Ratio

90%Confidence Interval

Ln(C max )

1.13

0.95 – 1.35

Ln(AUC t )

1.10

0.92 – 1.32

Ln(AUC i )

1.12

0.95 – 1.32

Ln(C max /AUC i )

1.01

0.89 – 1.14

Ln(t 1/2 )

1.18

1.02 – 1.37

Ln(MRT)

1.07

0.97 – 1.20

t max

1.05

0.86 – 1.29